| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 321,6 k € | -13.4% | 371,4 k € | +26.6% | 293,4 k € | +43.0% | 205,1 k € | +18.3% | 173,5 k € | +0.7% | 172,3 k € | -12.5% | 196,9 k € | +45.4% | 135,5 k € | -46.5% | 253,1 k € | +25.3% | 202,0 k € | +3.4% | 195,4 k € | +36.8% | 142,8 k € | +12.8% | 126,6 k € | -39.9% | 210,8 k € | -0.2% | 211,3 k € | +22.6% | 172,3 k € | +4.0% | 165,7 k € | |
| EBITDA | 317,4 k € | -14.3% | 370,6 k € | +26.9% | 292,2 k € | +42.9% | 204,4 k € | +18.3% | 172,8 k € | +0.5% | 171,9 k € | -12.7% | 196,8 k € | +45.5% | 135,3 k € | -46.5% | 253,0 k € | +25.3% | 201,9 k € | +3.6% | 194,8 k € | +36.6% | 142,6 k € | +12.7% | 126,5 k € | -39.9% | 210,6 k € | -0.3% | 211,2 k € | +22.7% | 172,2 k € | +3.9% | 165,7 k € | |
| Operating profit | 309,7 k € | -13.6% | 358,4 k € | +28.2% | 279,6 k € | +46.0% | 191,5 k € | +30.2% | 147,0 k € | +0.7% | 146,1 k € | -14.4% | 170,6 k € | +72.8% | 98,7 k € | -53.9% | 213,9 k € | +36.3% | 156,9 k € | +6.6% | 147,2 k € | +23.3% | 119,4 k € | +15.9% | 103,0 k € | -44.7% | 186,1 k € | -0.9% | 187,8 k € | +26.4% | 148,5 k € | +5.8% | 140,4 k € | |
| Profit/loss | 219,8 k € | -12.0% | 249,7 k € | +31.0% | 190,5 k € | +43.7% | 132,6 k € | +26.9% | 104,5 k € | +4.4% | 100,1 k € | -12.8% | 114,8 k € | +86.9% | 61,4 k € | -52.8% | 130,2 k € | +52.0% | 85,6 k € | -7.8% | 92,9 k € | +13.5% | 81,8 k € | +14.8% | 71,3 k € | -40.5% | 119,7 k € | +3.4% | 115,7 k € | +39.3% | 83,1 k € | +0.8% | 82,4 k € | |
| Equity | 999,1 k € | +11.7% | 894,1 k € | +26.7% | 705,9 k € | +9.4% | 645,5 k € | -12.0% | 733,6 k € | -0.1% | 734,3 k € | +15.8% | 634,2 k € | +22.1% | 519,4 k € | -28.6% | 727,1 k € | +21.8% | 596,9 k € | +16.8% | 511,3 k € | +22.2% | 418,4 k € | +8.8% | 384,5 k € | +22.7% | 313,3 k € | +61.8% | 193,6 k € | +148.6% | 77,9 k € | -17.9% | 94,8 k € | |
| Total assets | 1,1 M € | +9.4% | 968,5 k € | -6.9% | 1,0 M € | +17.3% | 886,6 k € | +10.3% | 803,7 k € | -3.2% | 830,6 k € | +9.4% | 759,5 k € | +22.1% | 621,8 k € | -28.2% | 866,1 k € | +16.1% | 745,9 k € | +10.1% | 677,6 k € | +48.9% | 455,1 k € | +13.0% | 402,8 k € | -19.0% | 497,0 k € | +2.4% | 485,5 k € | -3.2% | 501,5 k € | +25.5% | 399,7 k € | |
| Cash | 455,1 k € | +49.1% | 305,2 k € | -50.4% | 614,8 k € | -8.4% | 671,2 k € | +15.9% | 579,0 k € | -1.7% | 589,2 k € | +14.8% | 513,2 k € | +34.1% | 382,6 k € | -37.2% | 609,7 k € | +26.9% | 480,5 k € | +6.3% | 451,8 k € | +34.0% | 337,3 k € | +38.3% | 243,8 k € | -28.0% | 338,6 k € | +10.5% | 306,5 k € | +3.6% | 295,8 k € | +71.4% | 172,5 k € | |
| Debts | 57,9 k € | -13.1% | 66,6 k € | -79.6% | 326,6 k € | +36.9% | 238,6 k € | +240.5% | 70,1 k € | -27.2% | 96,3 k € | -23.1% | 125,2 k € | +22.3% | 102,4 k € | -26.4% | 139,1 k € | -6.7% | 149,0 k € | -10.2% | 165,9 k € | +357.4% | 36,3 k € | +177.3% | 13,1 k € | -92.5% | 173,8 k € | -37.5% | 278,1 k € | -31.5% | 406,1 k € | +41.3% | 287,5 k € | |
Private limited company · Brugge · incorporated on 08/07/2008
Private limited company profitable and well capitalised. Cash position rising (+49.1%).
Acceptable counterparty for a moderate engagement. Require 2 fiscal years of detailed accounts before any significant exposure. The abridged model hides revenue.
DR. HANS ORLENT is a Private limited company incorporated in 2008. Its main activity is: Other human health activities. Its registered office is in Brugge.
Key indicators
7-day free trial, no credit card required.
7-day free trial, no credit card required.
7-day free trial, no credit card required.
Source: Belgian Official Gazette